Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings

@article{Gualtieri2016UnifiNF,
  title={Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings},
  author={Fulvio Gualtieri},
  journal={Journal of Enzyme Inhibition and Medicinal Chemistry},
  year={2016},
  volume={31},
  pages={187 - 194}
}
  • F. Gualtieri
  • Published 3 March 2016
  • Physics
  • Journal of Enzyme Inhibition and Medicinal Chemistry
Abstract This paper is a review of the work of my former academic group of research in the past 15 years, in the field of cognition enhancers (also called nootropics) that identified two very potent molecules: Unifiram and Sunifiram that for a variety of reasons were not protected by a patent. Some 12 years after their disclosure (2000) I casually found that on the web, there were dozens of sites offering Unifiram and Sunifiram as drugs that improve cognition in healthy individuals even if only… 
Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals
TLDR
This paper aims to provide an overview on the prevalence of use; putative neuroenhancement benefits and possible harms relating to the intake of the most popular CEs in healthy individuals; and the non-medical use of any potent psychotropic raises serious ethical and legal issues.
A Study of the Metabolism of the New Nootropic Preparation Unifiram by Ultra-High Performance Liquid Chromatography–High-Resolution Mass Spectrometry
Abstract The metabolism of the new nootropic drug unifiram is considered; this drug supposedly has significantly higher activity than that of piracetam, and it is under clinical trials as a means of
Novel Sunifiram-carbamate hybrids as potential dual acetylcholinesterase inhibitor and NMDAR co-agonist: simulation-guided analogue design and pharmacological screening
TLDR
Findings presented here showcase highly potential cholinergic agents, with expected partial agonist activity towards glycine binding pocket of NMDAR which could lead to development and optimisation of novel nootropic drugs.
N-Acylbenzotriazole: convenient approach for protecting group-free monoacylation of symmetric diamines
TLDR
The method described herein enable stepwise acylation of aliphatic diamines such as ethylenediamine and piperazine with two different N-acylbenzotriazoles affording unsymmetrical substituted diamines that can be used for construction of pharmaceutically important targets such as drugs, foldamers, and drug conjugates.

References

SHOWING 1-10 OF 51 REFERENCES
Cognition enhancers between treating and doping the mind.
Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs.
TLDR
Reasons for the problems encountered by nootropics, compounds therapeutically available and those in development, their structure activity relationships and mechanisms of action are discussed and the class is examined in more detail.
Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014.
TLDR
The present review covers the evolution of research in this field through March 2014, and describes drugs interacting with 42 receptors versus 32 receptors in the first paper.
Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
TLDR
The present review covers the evolution of research in this field through April 2014 and describes drugs interacting with 60 enzymes versus 43 enzymes in the first paper.
Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs.
Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers.
TLDR
In vitro experiments, performed on hippocampal slices, supported the hypothesis of a role of the AMPA receptors for the cognition-enhancing properties of unifiram and sun ifiram.
DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer
TLDR
Results indicate that DM235, a compound structurally related to piracetam, is a novel nootropic endowed with the capability to prevent cognitive deficits at very low doses, and its potency is about 1,000 times higher than that of the most active Piracetam-like compounds.
Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.
TLDR
This review covers the evolution of research in this field over the last 25 years and proposes assigning drugs to 19 categories according to their mechanism of action.
Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
TLDR
The review covers the evolution of research in this field over the last 25 years and proposes assigning drugs to 18 categories according to their mechanism(s) of action.
...
...